| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 78.0 | 69.0 |
| Gross profit | 50.7 | 45.8 |
| Profit before tax | -12.2 | -15.6 |
| Net income | -12.5 | -15.7 |
| EPS (diluted, $ a share) | $-0.19 | $-0.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +13.0% |
|---|---|
| Gross margin | 65.0% |
| Operating margin | -10.8% |
10-Q filed with the SEC, NASDAQ: EOLS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Evolus, Inc.: key numbers
- Share price
- $6.63Close, Nov 16
- Market cap
- $439M
- Shares outstanding
- 66.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Evolus, Inc.
All →Evolus Earnings Call: Key Takeaways
Evolus delivered its fourth consecutive positive adjusted EBITDA quarter, demonstrating strong operating leverage as revenue grew 13% while non-GAAP operating expenses remained disciplined.
- Call
- Nov 4, 2026, 4:30 PM ET
Evolus Financial Results
Evolus reported Q3 2026 global net revenue of $78.0 million, a 13% increase year-over-year, driven by growth in its Jeuveau toxin and HA gel portfolio. The company achieved its fourth consecutive quarter of positive Adjusted EBITDA at $1.2 million and reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million.
- Term
- Q3 2026
“Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company. Jeuveau® remains a durable growth engine, and our hyaluronic acid (HA) gel portfolio is gaining meaningful share and becoming an increasingly important contributor to the business.”
David Moatazedi, President and Chief Executive Officer
“Along with our commercial progress, we are building a robust innovation pipeline that broadens our long-term opportunity. Our partnership with IBSA to develop and commercialize Profhilo® in the United States establishes the foundation for skin quality as a third category within our facial injectable platform.”
David Moatazedi, President and Chief Executive Officer